Improving the dromedary antibody response: The hunt for the ideal camel adjuvant

Journal of Camel Practice and Research

Volumn 18, Issue 1, 2011, Pages 35-46

  Eckersley, A M ^a   Petrovsky, N ^b   Kinne, J ^a   Wernery, R ^a   Wernery, U ^a  

^a CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Adjuvant; Advax; Antibody; Camel; Dromedary; Gerbu and alum; Inflammation; Montanide

Indexed keywords

AFRICAN HORSESICKNESS VIRUS; BACTERIA (MICROORGANISMS); BURKHOLDERIA MALLEI; CAMELIDAE; CAMELUS DROMEDARIUS;

EID: 84862585144     PISSN: 09716777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Abbas B and Agab H (2002). A review of camel brucellosis. Preventative Veterinary Medicine 55:47-56. (Pubitemid 35181117)
2. Bomford R, Stapleton M, Winsor S, McKnight A and Andronova T (1992). The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Research Human Retroviruses 8:1765-1771.
3. Brewer JM, Conacher M, Hunter CA Markus M, Brombacher F and Alexander J (1999). Aluminium Hydroxide Adjuvant Initiates Strong Antigen-Specific Th2 Responses in the Absence of IL-4- or IL-13-Mediated Signalling. Journal of Immunology 163:6448-6454.
4. Chapel HM and August PJ (1976). Report of nine cases of accidental injury to man with Freund's complete adjuvant. Clinical Experimental Immunology 24:538-541.
5. Cook DAN, Samarasekara CL, Wagstaff SC, Kinne J, Wernery U and Harrison RA (2010). Analysis of camelid IgG for antivenom development: serological responses of venom-immunised camels to prepare either monospecific or polyspecific antivenoms for West Africa. Toxicon 56:363-372.
6. Cox JC and Coulter AR (1997). Adjuvants - a classification on their modes of action. Vaccine 15:248-256. (Pubitemid 27116125)
7. Deckers N, Saerens D, Kanobana K, Conrath K, Victor B, Wernery U, Vercruysse J, Muyldermans S and Dorny P (2009). Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. International Journal of Parasitology 39:625-633.
8. Deffar K, Hengliang S, Liang L, Xingzhi W and Xiaojuan Z (2009). Nanobodies, the new concept of antibody engineering. African Journal of Biotechnology 8:2645-2652.
9. Dvorak GD and Spickler AR (2008). Glanders. Journal of the American Veterinary Medical Association 233:570-577.
10. Edelmen R (1980). Vaccine Adjuvants. Revue of Infectious Diseases 2:370-383.
11. Freund J, Casals J and Hosmer EP (1937). Sensitisation and antibody formation after injection of tubercle bacilli and paraffin oil. Proceedings of the Society for Experimental Biology and Medicine 37:509-513.
12. Gaffney RM and Casley-Smith JR (2005). Excess plasma proteins as a cause of chronic inflammation and lymphoedema: Biochemical estimations. Journal of Pathology 133:229-242.
13. Gupta RK and Sibera GR (1995). Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13:1263-1276.
14. Hendrick MJ, Kass PH, McGill LD and Tizard I (1994). Postvaccinal Sarcomas in Cats. Journal of the National Cancer Institute 86:341-343.
15. House JA, Lombard M, Dubourget P, House C and Mebus CA. (1994). Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine. Vaccine 12:142-144. (Pubitemid 24041932)
16. Inoue K, Takano H, Yanagisawa R, Sakurai M, Ichinose T, Sadakane K and Yoshikawa T (2005). Effects of nano particles on antigen-related airway inflammation in mice. Respiratory Research 6:106.
17. Lehavi O, Aizenstien O, Katz LH and Hourvitz A (2002). Glanders-a potential disease for biological warfare in humans and animals. Harefuah 141:88-91.
18. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, Toriniwa H and Petrovsky N. (2010). An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralising antibody against homologous and heterologous flaviviruses. Journal of General Virology 91:1407-1417.
19. Mackowiak PA (1981). Direct Effects of Hyperthermia on Pathogenic Microorganisms: Teleogenic implications with Regard to Fever. Revue Infectious Diseases 3:508-520.
20. Matzinger P. (2002). The danger model: a renewed sense of self. Science. 296:301-305.
21. Mosser DM (2003). The many faces of macrophage activation. Journal of Leukocyte Biology 73:209-212.
22. OIE (2008). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, 6th Edn. OIE, Paris, France, pp 833-837.
23. Petrovsky N and Aguilar JC (2004). Vaccine Adjuvants: Current State and Future Trends. Immunology and Cell Biology 82:488-496. (Pubitemid 39421058)
24. Petrovsky N (2006). Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 12, Supplement 2: 26-29.
25. Petrovsky N, Heinzel S, Honda Y and Lyons AB (2007). New-Age Vaccine Adjuvants: Friend or Foe? http:// biopharminternational.findpharma.com/biopharm/ article/articleDetail.jsp?id=444996&sk=&date=&pag eID=5
26. Petrovsky N (2008). Freeing vaccine adjuvants from dangerous ' immunological dogma. Expert Revue Vaccines 7:7-10.
27. Ramon G (1925). Sur L'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphteique. Bulletin de Ia Socié té Centrale Medicine Vétérinaire 101:227-234.
28. Serhan CN and Savill J (2005). Resolution of Inflammation: The beginning programs the end. Nature Immunology 6:1191-1197. (Pubitemid 43045627)
29. Stuart-Harris CH (1969). Adjuvant influenza vaccines. Bulletin WHO 41:617-621.
30. Vogel FR and Powell MF (1995). A summary compendium of vaccine adjuvants and excipients. In: Vaccine Design: the Subunit and Adjuvant Approach, Eds., Powell MF and Newman MJ. Plenum Publishing Corporation, New York, USA. pp 234-250.